- Home
- FIS vs INCY Comparison
FIS vs INCY Comparison
Compare FIS & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIS | INCY |
|---|---|---|
| Founded | 1968 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 17.0B |
| IPO Year | 2001 | 1994 |
Fundamental Metrics
Financial Performance| Metric | FIS | INCY |
|---|---|---|
| Price | $34.98 | $127.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 21 |
| Target Price | $72.23 | ★ $103.52 |
| AVG Volume (30 Days) | ★ 4.8M | 1.2M |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.81% | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | ★ 5.03 | 1.47 |
| Revenue | ★ $10,677,000,000.00 | $3,394,635,000.00 |
| Revenue This Year | $30.41 | $10.44 |
| Revenue Next Year | $4.76 | $10.99 |
| P/E Ratio | ★ $7.00 | $84.80 |
| Revenue Growth | 5.43 | ★ 13.67 |
| 52 Week Low | $35.19 | $81.09 |
| 52 Week High | $69.14 | $132.60 |
Technical Indicators
Market Signals| Indicator | FIS | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 30.80 | 51.08 |
| Support Level | N/A | $120.79 |
| Resistance Level | $43.83 | $131.13 |
| Average True Range (ATR) | 1.19 | 3.01 |
| MACD | -0.40 | -0.27 |
| Stochastic Oscillator | 6.48 | 46.76 |
Price Performance
Historical ComparisonAbout FIS Fidelity National Information Services Inc.
Fidelity National Information Services provides core processing and ancillary services to banks, but its business has expanded over time. By acquiring SunGard in 2015, the company now provides record-keeping and other services to investment firms. In a recent deal with Global Payments, FIS sold off its remaining interest in Worldpay and acquired Global Payment's issuer processing business.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.